Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC（neoSCORE）

NCT04459611 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

BIOLOGICAL: sintilimab
DRUG: pemetrexed
DRUG: Carboplatin
DRUG: albumin-bound paclitaxel

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University